Get the Stockscreener App
13.48
28.26%
2.97
After Hours:
13.94
0.46
+3.41%
Evolus Inc stock is traded at $13.48, with a volume of 2.92M.
It is up +28.26% in the last 24 hours and up +23.78% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$10.51
Open:
$12.98
24h Volume:
2.92M
Relative Volume:
4.49
Market Cap:
$853.57M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-12.48
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
+42.34%
1M Performance:
+23.78%
6M Performance:
+12.71%
1Y Performance:
+13.76%
1-Day Range:
$12.74
$14.49
1-Week Range:
$9.64
$14.49
52-Week Range:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
13.48 | 853.57M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
Evolus projects robust 2025 growth with upcoming product launches - MSN
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates - Benzinga
Evolus Shares Surge 34% on Record Q4 Revenue and FDA Approval Ex - GuruFocus.com
Evolus (NASDAQ:EOLS) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why - MSN
Evolus (NASDAQ:EOLS) Shares Gap UpTime to Buy? - MarketBeat
Evolus announces Q4 preliminary unaudited net revenue of $79M - MSN
Evolus shares surge on strong Q4 results and upbeat 2025 outlook - MSN
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
Evolus Shares Rise on Jump in Revenue - MarketWatch
Evolus, Inc. Provides Financial Guidance for the Full Year of 2025 -January 21, 2025 at 08:00 am EST - Marketscreener.com
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Trend Tracker for (EOLS) - Stock Traders Daily
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 (NASDAQ:EOLS) - Seeking Alpha
Evolus (NASDAQ:EOLS) Hits New 1-Year LowHere's Why - MarketBeat
Possible Bearish Signals With Evolus Insiders Disposing Stock - Simply Wall St
Evolus stock touches 52-week low at $10.23 amid market shifts - Investing.com Nigeria
Evolus (NASDAQ:EOLS) Sets New 52-Week LowHere's What Happened - MarketBeat
EVOLUS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased E - PR Newswire
(EOLS) Technical Data - Stock Traders Daily
Barclays PLC Grows Stake in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27 - GuruFocus.com
Evolus CFO Sandra Beaver sells shares worth $17,211 By Investing.com - Investing.com Australia
Evolus chief medical officer sells shares worth $24,438 By Investing.com - Investing.com Australia
Evolus chief medical officer sells shares worth $24,438 - Investing.com India
Evolus CFO Sandra Beaver sells shares worth $17,211 - Investing.com India
Evolus, Inc. (NASDAQ:EOLS) CFO Sells $17,208.10 in Stock - MarketBeat
Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock - MarketBeat
Evolus CEO David Moatazedi sells $113,966 in stock By Investing.com - Investing.com Nigeria
Evolus CEO David Moatazedi sells $113,966 in stock - Investing.com
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by State Street Corp - MarketBeat
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability - Yahoo Finance
Lord Abbett & CO. LLC Acquires 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Stock Options Galore! Discover Evolus’ Latest Move - Jomfruland.net
(EOLS) On The My Stocks Page - Stock Traders Daily
Evolus Expands Team with Strategic Equity Incentives Package for 20 New Hires - StockTitan
Evolus's SWOT analysis: aesthetics firm's stock poised for growth By Investing.com - Investing.com South Africa
Evolus's SWOT analysis: aesthetics firm's stock poised for growth - Investing.com
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):